CN102170884A - 口服制剂 - Google Patents

口服制剂 Download PDF

Info

Publication number
CN102170884A
CN102170884A CN200980139559XA CN200980139559A CN102170884A CN 102170884 A CN102170884 A CN 102170884A CN 200980139559X A CN200980139559X A CN 200980139559XA CN 200980139559 A CN200980139559 A CN 200980139559A CN 102170884 A CN102170884 A CN 102170884A
Authority
CN
China
Prior art keywords
disorder
chemical compound
compositions
formula
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200980139559XA
Other languages
English (en)
Chinese (zh)
Inventor
R·霍尔姆
C·考
B·威卢姆森
K·P·赫特尔
C·K·奥尔森
L·布卢恩
K·K·索拜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41217546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102170884(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN102170884A publication Critical patent/CN102170884A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN200980139559XA 2008-10-03 2009-10-01 口服制剂 Pending CN102170884A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US10237708P 2008-10-03 2008-10-03
DKPA200801392 2008-10-03
DKPA200801392 2008-10-03
US61/102377 2008-10-03
US17639209P 2009-05-07 2009-05-07
DKPA200900591 2009-05-07
DKPA200900591 2009-05-07
US61/176392 2009-05-07
PCT/DK2009/050258 WO2010037398A1 (en) 2008-10-03 2009-10-01 Oral formulation

Publications (1)

Publication Number Publication Date
CN102170884A true CN102170884A (zh) 2011-08-31

Family

ID=41217546

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980139559XA Pending CN102170884A (zh) 2008-10-03 2009-10-01 口服制剂

Country Status (16)

Country Link
US (1) US20110178094A1 (enExample)
EP (1) EP2344163A1 (enExample)
JP (1) JP2012504560A (enExample)
KR (1) KR20110081176A (enExample)
CN (1) CN102170884A (enExample)
AR (1) AR073755A1 (enExample)
AU (1) AU2009298264A1 (enExample)
BR (1) BRPI0919165A2 (enExample)
CA (1) CA2732613A1 (enExample)
CO (1) CO6321158A2 (enExample)
EA (1) EA201170512A1 (enExample)
IL (1) IL210235A0 (enExample)
MX (1) MX2011001044A (enExample)
NZ (1) NZ590897A (enExample)
WO (1) WO2010037398A1 (enExample)
ZA (1) ZA201102446B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
MX2010012037A (es) * 2008-05-07 2010-11-30 Lundbeck & Co As H Composiciones y uso utiles para tratar trastornos cognitivos.
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
LT3135656T (lt) 2011-06-20 2019-04-25 H. Lundbeck A/S Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui
JO3421B1 (ar) * 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
CN112930341A (zh) 2018-10-29 2021-06-08 H.隆德贝克有限公司 无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐
CN113056457B (zh) 2018-12-03 2025-06-20 H.隆德贝克有限公司 用于治疗cns疾病的前药

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) * 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
DE3139970A1 (de) * 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) * 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CA2091204C (en) * 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
CA2132411A1 (en) * 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6410794B1 (en) * 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US5807897A (en) * 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
ES2211080T3 (es) * 1998-05-01 2004-07-01 Pfizer Products Inc. Procedimiento para la produccion de sertralina tetralona enantiomericamente pura u opticamente enriquecida usando cromatografia continua.
IN187170B (enExample) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
AU2002359857B8 (en) * 2001-12-28 2009-01-08 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
CA2536073A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
JP2008530039A (ja) * 2005-02-16 2008-08-07 ハー・ルンドベック・アクチエゼルスカベット トランス−１−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジンの酒石酸塩およびリンゴ酸塩
UY30535A1 (es) * 2006-08-10 2008-03-31 Cipla Ltd Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
MX2010012037A (es) * 2008-05-07 2010-11-30 Lundbeck & Co As H Composiciones y uso utiles para tratar trastornos cognitivos.

Also Published As

Publication number Publication date
WO2010037398A1 (en) 2010-04-08
EA201170512A1 (ru) 2011-08-30
EP2344163A1 (en) 2011-07-20
KR20110081176A (ko) 2011-07-13
MX2011001044A (es) 2011-03-21
US20110178094A1 (en) 2011-07-21
NZ590897A (en) 2012-07-27
BRPI0919165A2 (pt) 2015-12-08
AR073755A1 (es) 2010-12-01
IL210235A0 (en) 2011-03-31
ZA201102446B (en) 2012-07-25
CO6321158A2 (es) 2011-09-20
CA2732613A1 (en) 2010-04-08
JP2012504560A (ja) 2012-02-23
AU2009298264A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
JP5401327B2 (ja) 溶出性の改善された錠剤
JP2012504560A (ja) 経口製剤
CN101460150B (zh) 用于口腔崩解片剂的可直接压片复合物
CN107028900A (zh) 快速分散颗粒、口腔崩解片以及方法
JP4633469B2 (ja) 経口固形医薬
JP4805234B2 (ja) 経口固形医薬
US20220323429A1 (en) Pimavanserin for treating neurodegenerative diseases
AU2009243813B2 (en) Method for treating cognitive deficits
US20150157628A1 (en) Pharmaceutical compositions of Lurasidone and Process for preparation thereof
US20120010216A1 (en) Pharmaceutical compositions containing vanoxerine
JP6639368B2 (ja) 糖尿病治療用固形製剤
CN101890169A (zh) 莫西沙星口服制剂及其制备方法
Dhiman et al. Formulation and In-Vitro evaluation of fast dissolving tablets of telmisartan.
JP2009001520A (ja) ジフェンヒドラミン含有固形製剤
HK1161118A (en) Oral formulation
CN107441051A (zh) 一种盐酸普罗帕酮微片及其制备方法
JP6558530B2 (ja) アリピプラゾール医薬品製剤
CN105963273A (zh) 甲磺酸帕罗西汀胶囊及其制备方法
CN106474080A (zh) 一种孟鲁斯特纳口崩片及其制备方法
CN116763746A (zh) 一种布瑞哌唑口崩片及其制备方法
CN117442573A (zh) 一种右佐匹克隆药物组合物
RU2588840C1 (ru) Таблетки кветиапина с пролонгированным высвобождением и способ их получения
Meenakshisunderam 2) Patent Application Publication o Pub. No.: US 2015/0157628A1
CN104324383A (zh) 一种盐酸苯海拉明药物组合物及其制备方法
HK1138191A (en) Oral solid composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1161118

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110831

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1161118

Country of ref document: HK